CPT code 82233 represents a laboratory chemistry assay for beta–amyloid 40, a protein biomarker linked to Alzheimer’s disease pathology. As interest in biomarker-driven diagnosis and monitoring of neurodegenerative conditions increases, assays such as this are becoming more clinically relevant for research settings and specialty diagnostic workflows. The code captures the analytic component of measuring beta–amyloid 40 in a clinical laboratory setting.

Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a national-level overview of clinical context for beta–amyloid 40 testing, the typical laboratory service setting, and which payers commonly adjudicate claims for biomarker assays. The publication outlines benchmarks and coverage considerations where available, highlights coding context for laboratory chemistry assays, and summarizes policy and clinical implications for stakeholders in diagnostics, neurology, and laboratory services.

This report is intended to inform providers, billing specialists, and policy analysts about the clinical purpose of CPT code 82233, payer coverage landscape, and the types of insights available on utilization and reimbursement for beta–amyloid 40 testing. Data not available in the input are noted where applicable.